Area of research
Molecular Biology · Immunology
Research interest
Research interests include Angiogenesis and VEGF in Cancer, Immunotherapy and Immune Responses, RNA Interference and Gene Delivery, and Cancer Research and Treatments.
LncRNA ELFN1-AS1 maintains the stemness of colorectal cancer by preventing ubiquitinated degradation of the hnRNPA1 protein.
Tumor cell-intrinsic PD-1 in malignant ascites drives ovarian cancer progression via MAPK/ERK signaling.
Cancer stem cells: Bridging microenvironmental interactions and clinical therapy.
Characterizing neuroinflammation and identifying prenatal diagnostic markers for neural tube defects through integrated multi-omics analysis.
Colitis-associated carcinogenesis: crosstalk between tumors, immune cells and gut microbiota.
Acquired semi-squamatization during chemotherapy suggests differentiation as a therapeutic strategy for bladder cancer
A novel membrane-bound interleukin-2 promotes NK-92 cell persistence and anti-tumor activity.
3D Printing Mini-Capsule Device for Islet Delivery to Treat Type 1 Diabetes.
Dexamethasone enhances the lung metastasis of breast cancer via a PI3K-SGK1-CTGF pathway.
Intestinal epithelium-derived BATF3 promotes colitis-associated colon cancer through facilitating CXCL5-mediated neutrophils recruitment.
BATF2 prevents glioblastoma multiforme progression by inhibiting recruitment of myeloid-derived suppressor cells
Secretogranin II impairs tumor growth and angiogenesis by promoting degradation of hypoxia-inducible factor-1α in colorectal cancer.
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
TFAP2C facilitates somatic cell reprogramming by inhibiting c-Myc-dependent apoptosis and promoting mesenchymal-to-epithelial transition.
A Novel Antitumor Strategy: Simultaneously Inhibiting Angiogenesis and Complement by Targeting VEGFA/PIGF and C3b/C4b.
Hypomethylation of GDNF family receptor alpha 1 promotes epithelial-mesenchymal transition and predicts metastasis of colorectal cancer.
Integrative analysis provides multi-omics evidence for the pathogenesis of placenta percreta.
SARI suppresses colitis-associated cancer development by maintaining MCP-1-mediated tumour-associated macrophage recruitment.
SARI prevents ocular angiogenesis and inflammation in mice.
Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy.
Targeted demethylation of the SARI promotor impairs colon tumour growth.
Temporal expression and functional analysis of long non-coding RNAs in colorectal cancer initiation.
SARI attenuates colon inflammation by promoting STAT1 degradation in intestinal epithelial cells.
Human Adipose-Derived Mesenchymal Stem Cell-Secreted CXCL1 and CXCL8 Facilitate Breast Tumor Growth By Promoting Angiogenesis